Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Rotavirus Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Rotavirus Infections - Pipeline Review, H2 2014', provides an overview of the Rotavirus Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rotavirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rotavirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rotavirus Infections Overview 7 Therapeutics Development 8 Pipeline Products for Rotavirus Infections - Overview 8 Pipeline Products for Rotavirus Infections - Comparative Analysis 9 Rotavirus Infections - Therapeutics under Development by Companies 10 Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes 12 Rotavirus Infections - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Rotavirus Infections - Products under Development by Companies 16 Rotavirus Infections - Products under Investigation by Universities/Institutes 17 Rotavirus Infections - Companies Involved in Therapeutics Development 18 Takeda Pharmaceutical Company Limited 18 Biological E. Limited 19 Medicago Inc. 20 Bharat Biotech International Limited 21 Shantha Biotechnics Limited 22 Sinovac Biotech Ltd. 23 Seek 24 Serum Institute of India Limited 25 Beijing Minhai Biotechnology Co., Ltd 26 Sanofi Pasteur SA 27 Rotavirus Infections - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 ORV-116E - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Rotavirus Vaccine - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Rotavirus Vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Rotavirus Vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vaccine for Rotavirus Infection - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 P2-VP8 Rotavirus Vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Rotavirus Vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 T-Cell Vaccine for Rotavirus - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Rotavirus VLP Vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Protein to Activate TLR5 for Rotavirus Infections and GVHD - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Vaccine for Rotavirus Infections - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Anti-HRV-3IgY - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 rotavirus vaccine (pentavalent) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Subunit Vaccine for Rotavirus Infections - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Monoclonal Antibodies to Inhibit VP6 for Rotavirus Infections - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Rotavirus Infections - Recent Pipeline Updates 52 Rotavirus Infections - Dormant Projects 53 Rotavirus Infections - Product Development Milestones 54 Featured News & Press Releases 54 Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate 54 May 14, 2013: Bharat Biotech's Rotavirus Vaccine Demonstrates Strong Efficacy In Phase III Clinical Trial 54 Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus 56 Apr 26, 2012: GSK's Rotarix To Be Introduced In Ghana 57 Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan 57 Jun 06, 2011: Bharat Biotech Announces Price Of Potential Vaccine Against Rotavirus Diarrhoea 58 May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Rotavirus Infections, H2 2014 8 Number of Products under Development for Rotavirus Infections - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 11 Number of Products under Investigation by Universities/Institutes, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Rotavirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 18 Rotavirus Infections - Pipeline by Biological E. Limited, H2 2014 19 Rotavirus Infections - Pipeline by Medicago Inc., H2 2014 20 Rotavirus Infections - Pipeline by Bharat Biotech International Limited, H2 2014 21 Rotavirus Infections - Pipeline by Shantha Biotechnics Limited, H2 2014 22 Rotavirus Infections - Pipeline by Sinovac Biotech Ltd., H2 2014 23 Rotavirus Infections - Pipeline by Seek, H2 2014 24 Rotavirus Infections - Pipeline by Serum Institute of India Limited, H2 2014 25 Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 26 Rotavirus Infections - Pipeline by Sanofi Pasteur SA, H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Number of Products by Stage and Target, H2 2014 30 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Rotavirus Infections Therapeutics - Recent Pipeline Updates, H2 2014 52 Rotavirus Infections - Dormant Projects, H2 2014 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
